Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Medical Oncology
•
Ovarian Cancer
Are there any data to suggest efficacy of pembrolizumab for MSI-H for recurrent, progressive, platinum-resistant mucinous ovarian cancer?
Related Questions
How should PARP inhibitors be incorporated into clinical practice in later line/maintenance of platinum-sensitive ovarian cancer for PARP inhibitor-naïve patients?
What hormonal therapy, if any, would you offer for adjuvant treatment of stage IC ER-/PR+ low grade serous ovarian cancer?
What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
After seeing results from GOG238, is there a subset of patients that might still benefit from chemoradiation for centrally recurrent endometrial cancer?
Do you recommend progesterone for endometrial protection in a young woman on estrogen replacement therapy for iatrogenic menopause after definitive radiation therapy for locally advanced cervical cancer?
How do you treat cervical cancer with an ovarian metastasis?
What adjuvant therapy would you recommend for a postmenopausal female with a dedifferentiated endometrial cancer, extensive LVI but negative nodes, MSI-high (somatic) and >50% myometrial invasion?
